CoChat

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Open access

Published version of a preprint

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)–targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such as those in advanced prostate cancer. This first-in-human study reports monotherapy dose exploration for patients with metastatic castration-resistant prostate cancer (mCRPC), primarily taxane pretreated. Ninety-seven patients received ≥1 intravenous dose ranging from 0.001 to 2.0 mg weekly or every 2 weeks. MTD was identified as 1.5 mg i.v. weekly via a 3-step dose. The most common treatment-related adverse events were cytokine release syndrome (CRS; 72%), fatigue (45%), and myalgia (34%). CRS occurred primarily during cycle 1 and improved with premedication and step dosing. Prostate-specific antigen (PSA) and RECIST responses across cohorts were encouraging [49% PSA50; 24% objective response rate (ORR)], with greater frequency at target doses ≥0.75 mg (59% PSA50; 41% ORR). Xaluritamig is a novel immunotherapy for prostate cancer that has shown encouraging results supporting further development. Significance: Xaluritamig demonstrated encouraging responses (PSA and RECIST) compared with historical established treatments for patients with late-line mCRPC. This study provides proof of concept for T-cell engagers as a potential treatment for prostate cancer, validates STEAP1 as a target, and supports further clinical investigation of xaluritamig in prostate cancer. See related commentary by Hage Chehade et al., p. 20. See related article by Nolan-Stevaux et al., p. 90. This article is featured in Selected Articles from This Issue, p. 5

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-23-0964

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. A, Frequency and highest-grade AEs occurring in ≥20% of patients treated with xaluritamig across all cohorts, TEAE vs. TRAEs (defined by the investigator as having reasonable possibility of being caused by xaluritamig). B, Incidence and grade of CRS (32) by cycle and dose schedule. Cohort 10 was excluded (0.1–1.0 mg), as dosing schedule was adjusted for the remaining patients after initial patients with a 10-fold dose increase in 1 step experienced DLTs. ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Figure 1. A, Frequency and highest-grade AEs occurring in ≥20% of patients treated with xaluritamig across all cohorts, TEAE vs. TRAEs (defined by the investigator as having reasonable possibility of being caused by xaluritamig). B, Incidence and grade of CRS (32) by cycle and dose schedule. Cohort 10 was excluded (0.1–1.0 mg), as dosing schedule was adjusted for the remaining patients after initial patients with a 10-fold dose increase in 1 step experienced DLTs. ALT, alanine aminotransferase; AST, aspartate aminotransferase.CC BY-NC-ND · PubMed Central
Figure 2. A, Mean (SD) xaluritamig serum concentration vs. time profile by individual cohorts for C1. Black dotted lines represent the lower end of the minimum predicted efficacious exposure based on EC90 for xaluritamig-mediated cell killing in vitro (74 ng/mL) and the upper end of the minimum predicted efficacious exposure based on IC50 for xaluritamig-mediated mouse tumor growth inhibition in vivo (259 ng/mL). Cohort 7c was dosed weekly for C1 and then switched to every 2 weeks starting C2 and beyond, which is not captured in this analysis. At the time of the data cut, there were 94 patients with at least one postbaseline xaluritamig concentration. T-cell pharmacodynamic biomarker response through the first infusion period is dose dependent. Peripheral lymphocyte margination (B), CD8+CD69+ activated T cells as a percentage of total CD8+ T cells (C), and induction of secreted cytokines at the indicated time points after infusion (D). Lines represent median fold change or difference of population percentage from C1D1 predose values ± median average deviation. Transparent points depict individual observations. Sample sizes within each priming dose group at each time point are shown as a strip annotation across the top of each figure. EC, effective concentration; IC, inhibitory concentration.
Figure 2. A, Mean (SD) xaluritamig serum concentration vs. time profile by individual cohorts for C1. Black dotted lines represent the lower end of the minimum predicted efficacious exposure based on EC90 for xaluritamig-mediated cell killing in vitro (74 ng/mL) and the upper end of the minimum predicted efficacious exposure based on IC50 for xaluritamig-mediated mouse tumor growth inhibition in vivo (259 ng/mL). Cohort 7c was dosed weekly for C1 and then switched to every 2 weeks starting C2 and beyond, which is not captured in this analysis. At the time of the data cut, there were 94 patients with at least one postbaseline xaluritamig concentration. T-cell pharmacodynamic biomarker response through the first infusion period is dose dependent. Peripheral lymphocyte margination (B), CD8+CD69+ activated T cells as a percentage of total CD8+ T cells (C), and induction of secreted cytokines at the indicated time points after infusion (D). Lines represent median fold change or difference of population percentage from C1D1 predose values ± median average deviation. Transparent points depict individual observations. Sample sizes within each priming dose group at each time point are shown as a strip annotation across the top of each figure. EC, effective concentration; IC, inhibitory concentration.CC BY-NC-ND · PubMed Central
Figure 3. Clinical activity of xaluritamig in evaluable patients. A, Best PSA percentage change from baseline. Asterisk indicates confirmed PSA responders, and dashed lines indicate PSA50 and PSA90 declines. B, Best percentage change in size of tumor target lesions. Dashed line indicates 30% reduction in tumor SLD from baseline. C, Example of patient showing response by PSA and radiographic assessments: CT scan and PSA curve over time of a heavily pretreated 65-year-old patient with stage IV prostate adenocarcinoma. Patient was enrolled into Cohort 11 (3-step 1.5 mg target dose of xaluritamig). CT scans showed three target lesions (two liver, one lymph node) and multiple nontarget lesions in the liver as well as two lymph nodes during screening. Patient achieved 99% PSA decline from baseline on C7D1 and PR (37.3% reduction of target lesions) after 2 cycles, which was confirmed at 16 weeks and maintained after 24 weeks. AEs occurred during C1 of treatment and included recurrent CRS, tinea faciei (both grade 1), rash, and worsening of back pain (both grade 2). During further treatment cycles, rash (grade 1), myalgia, and hyperkalemia (both grade 2) were reported. Patient remains on treatment at the time of publication. Red arrows indicate sites of tumor. D, Time on treatment for patients in high-dose cohorts. PSA and RECIST responses [RECIST evaluable (gray bars) and non–RECIST evaluable (white bars)] are presented for patients in high-dose cohorts. Patients whose treatment was ongoing are noted by an arrowhead. Double parallel lines (//) represent patients who have extended beyond 48 weeks: one patient is ongoing treatment at 90 weeks, one is ongoing treatment at 84 weeks, and one ended treatment at 58 weeks. NE, not evaluable; PD, progressive disease; SD, stable disease; SLD, sum of longest diameters.
Figure 3. Clinical activity of xaluritamig in evaluable patients. A, Best PSA percentage change from baseline. Asterisk indicates confirmed PSA responders, and dashed lines indicate PSA50 and PSA90 declines. B, Best percentage change in size of tumor target lesions. Dashed line indicates 30% reduction in tumor SLD from baseline. C, Example of patient showing response by PSA and radiographic assessments: CT scan and PSA curve over time of a heavily pretreated 65-year-old patient with stage IV prostate adenocarcinoma. Patient was enrolled into Cohort 11 (3-step 1.5 mg target dose of xaluritamig). CT scans showed three target lesions (two liver, one lymph node) and multiple nontarget lesions in the liver as well as two lymph nodes during screening. Patient achieved 99% PSA decline from baseline on C7D1 and PR (37.3% reduction of target lesions) after 2 cycles, which was confirmed at 16 weeks and maintained after 24 weeks. AEs occurred during C1 of treatment and included recurrent CRS, tinea faciei (both grade 1), rash, and worsening of back pain (both grade 2). During further treatment cycles, rash (grade 1), myalgia, and hyperkalemia (both grade 2) were reported. Patient remains on treatment at the time of publication. Red arrows indicate sites of tumor. D, Time on treatment for patients in high-dose cohorts. PSA and RECIST responses [RECIST evaluable (gray bars) and non–RECIST evaluable (white bars)] are presented for patients in high-dose cohorts. Patients whose treatment was ongoing are noted by an arrowhead. Double parallel lines (//) represent patients who have extended beyond 48 weeks: one patient is ongoing treatment at 90 weeks, one is ongoing treatment at 84 weeks, and one ended treatment at 58 weeks. NE, not evaluable; PD, progressive disease; SD, stable disease; SLD, sum of longest diameters.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 125

Metadata

Authors
Kelly, W. K., Danila, D. C., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P. J., Armstrong, A. J., Pook, D., Kim, M., Dorff, T. B., Fischer, S., Lin, Y.-C., Horvath, L. G., Sumey, C., Yang, Z., Jurida, G., Smith, K. M., Connarn, J. N., Penny, H. L., Stieglmaier, J., & Appleman, L. J.
Affiliations
  • Thomas Jefferson University (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • National Taiwan University Hospital (TW)
  • Asan Medical Center (KR)
  • 7National Cancer Center Hospital East, Chiba, Japan.
  • Sarah Cannon (US)
  • Duke University (US)
  • Monash Health (AU)
  • Seoul National University (KR)
  • City Of Hope National Medical Center (US)
  • Kantonsspital St. Gallen (CH)
  • Linkou Chang Gung Memorial Hospital (TW)
  • The University of Sydney (AU)
  • 16Sanford Cancer Center, Sioux Falls, South Dakota.
  • Amgen (United States) (US)
  • Amgen (Germany) (DE)
  • UPMC Health System (US)
Corresponding author
Kelly, William K.
Venue
Cancer Discovery
Published
2023-10-20
Volume
14
Issue
1
Pages
76-89
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4387798677
Cited by
125
References
30
Citations by year
2026: 56 · 2025: 47 · 2024: 21 · 2023: 1
FWCI
23.03
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • The Medicine Forum (submittedVersion, cc-by-nc-nd)
Funders
Amgen
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
STEAP1, T-cell engagers, metastatic castration-resistant prostate cancer, dose escalation, maximum tolerated dose, cytokine release syndrome, taxane-pretreated patients, PSA response, RECIST response
MeSH terms
Antigens, Neoplasm, Humans, Immunotherapy, Male, Oxidoreductases, Treatment Outcome, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. https://app.cochat.ai/papers/10.1158/2159-8290.cd-23-0964
The paper
Kelly, W. K., Danila, D. C., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P. J., Armstrong, A. J., Pook, D., Kim, M., Dorff, T. B., Fischer, S., Lin, Y.-C., Horvath, L. G., Sumey, C., Yang, Z., Jurida, G., Smith, K. M., Connarn, J. N., Penny, H. L., . . . Appleman, L. J. (2024). Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-23-0964

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.